[go: up one dir, main page]

DK1076566T3 - Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet - Google Patents

Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet

Info

Publication number
DK1076566T3
DK1076566T3 DK99919755T DK99919755T DK1076566T3 DK 1076566 T3 DK1076566 T3 DK 1076566T3 DK 99919755 T DK99919755 T DK 99919755T DK 99919755 T DK99919755 T DK 99919755T DK 1076566 T3 DK1076566 T3 DK 1076566T3
Authority
DK
Denmark
Prior art keywords
antigen
express
constructively
attenuated salmonella
salmonella mutants
Prior art date
Application number
DK99919755T
Other languages
English (en)
Inventor
Marcelo Sztein
Myron M Levine
Fernando R Noriega
Original Assignee
Univ Maryland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Maryland filed Critical Univ Maryland
Application granted granted Critical
Publication of DK1076566T3 publication Critical patent/DK1076566T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/025Enterobacteriales, e.g. Enterobacter
    • A61K39/0275Salmonella
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/02Bacterial antigens
    • A61K39/08Clostridium, e.g. Clostridium tetani
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/255Salmonella (G)
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20Bacteria; Culture media therefor
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00Drug, bio-affecting and body treating compositions
    • Y10S424/831Drug, bio-affecting and body treating compositions involving capsular polysaccharide of bacterium, e.g. polyribosyl ribitol phosphate
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00Chemistry: molecular biology and microbiology
    • Y10S435/8215Microorganisms
    • Y10S435/822Microorganisms using bacteria or actinomycetales
    • Y10S435/879Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK99919755T 1998-05-13 1999-04-30 Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet DK1076566T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/076,761 US6190669B1 (en) 1998-05-13 1998-05-13 Attenuated mutants of salmonella which constitutively express the Vi antigen

Publications (1)

Publication Number Publication Date
DK1076566T3 true DK1076566T3 (da) 2006-11-13

Family

ID=22134022

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99919755T DK1076566T3 (da) 1998-05-13 1999-04-30 Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet

Country Status (16)

Country Link
US (1) US6190669B1 (da)
EP (1) EP1076566B1 (da)
JP (1) JP4363782B2 (da)
AT (1) ATE333285T1 (da)
AU (1) AU754795B2 (da)
CA (1) CA2328056C (da)
DE (1) DE69932425T2 (da)
DK (1) DK1076566T3 (da)
ES (1) ES2268864T3 (da)
HU (1) HUP0101747A3 (da)
MX (1) MXPA00011075A (da)
NO (1) NO20005672L (da)
NZ (1) NZ508110A (da)
PL (1) PL192378B1 (da)
WO (1) WO1999058146A1 (da)
ZA (1) ZA200006381B (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322645T2 (de) * 1992-07-31 1999-05-20 Medeva Holdings B.V., Amsterdam Expression rekombinanter fusionsproteine in attenuierten bakterien
GB9521568D0 (en) * 1995-10-20 1995-12-20 Lynxvale Ltd Delivery of biologically active polypeptides
US6797275B1 (en) * 1998-12-04 2004-09-28 The United States Of America As Represented By The Department Of Health And Human Services Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine
DE69930147T2 (de) * 1998-12-04 2007-01-11 University Of Manitoba, Winnipeg Zwei-schritte-verfahren zur impfung gegen chlamydia
US7026155B2 (en) * 1999-02-02 2006-04-11 Regents Of The University Of California Method of reducing bacterial proliferation
EP1112747B1 (en) * 1999-12-28 2004-06-16 Akzo Nobel N.V. Salmonella vaccine not inducing antibodies against flagellin or flagella
US6902736B2 (en) * 2000-04-20 2005-06-07 University Of Maryland, Baltimore Isolation and characterization of the csa operon (ETEC-CS4 pili) and methods of using same
US7780961B2 (en) * 2001-05-03 2010-08-24 Actogenix N.V. Self-containing Lactococcus strain
US7541043B2 (en) 2002-01-16 2009-06-02 The United States Of America As Represented By The Department Of Health And Human Services Vaccine for protection against Shigella sonnei disease
DE60319822T2 (de) * 2002-06-19 2009-06-04 Actogenix Nv Verfahren und mittel zur erhöhung der darmabsorption
WO2004046346A2 (en) * 2002-11-15 2004-06-03 Vib Vzw Self-containing lactobacillus strain
JP2009516503A (ja) * 2005-10-28 2009-04-23 ユニバーシティ オブ メリーランド, ボルチモア 弱毒化s・パラチフスa菌株およびその使用
US8137930B2 (en) 2005-10-28 2012-03-20 University Of Maryland, Baltimore Attenuated Salmonella enterica serovar paratyphi A and uses thereof
WO2007062371A2 (en) * 2005-11-23 2007-05-31 University Of Maryland, Baltimore Live vector vaccine and uses thereof
EP2119450B1 (en) 2005-11-29 2013-02-13 Actogenix N.V. Induction of mucosal tolerance to pancreatic islet beta-cell autoantigens
WO2007112518A1 (en) * 2006-03-20 2007-10-11 Vrije Universiteit Brussel Live attenuated salmonella vaccine
CA2646421A1 (en) * 2006-03-20 2007-10-11 Vrije Universiteit Brussel Live attenuated salmonella vaccine
EP2066339B1 (en) * 2006-09-18 2014-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses
ES2492468T3 (es) 2007-01-25 2014-09-09 Actogenix N.V. Tratamiento de enfermedad inmunitaria por administración a través de la mucosa de antígenos usando Lactobacillus genéticamente modificado
US20110020399A1 (en) * 2007-04-16 2011-01-27 University Of Maryland, Baltimore Vaccines and Immunomodulatory Therapies for Tularemia
NZ585776A (en) * 2007-10-30 2012-07-27 Univ Arkansas Compositions and methods of enhancing immune responses to flagellated bacterium
WO2009059298A2 (en) 2007-11-01 2009-05-07 Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancinc immune responses to eimeria
WO2010036226A1 (en) * 2008-09-26 2010-04-01 George Nelson Process for treatment of rheumatoid arthritis, tremors/parkinson's disease and multiple sclerosis
WO2010141143A2 (en) * 2009-04-21 2010-12-09 Vivocure, Inc. Engineered avirulent bacteria strains and use in medical treatments
CN102811734B (zh) 2010-01-21 2016-02-10 阿肯色大学评议会 增强免疫应答的疫苗载体和方法
ES2753142T3 (es) 2010-06-09 2020-04-07 Univ Arkansas Vacuna y métodos para reducir una infección por Campylobacter
US9833503B2 (en) 2012-02-24 2017-12-05 President And Fellows Of Harvard College Methods for displaying polypeptides and uses thereof
ES2968398T3 (es) 2013-02-14 2024-05-09 Univ Arkansas Composiciones y métodos para potenciar las respuestas inmunitarias a Eimeria o limitar la infección por Eimeria
EP3578190A1 (en) 2013-03-15 2019-12-11 The Board of Trustees of the University of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
TWI843057B (zh) 2016-05-03 2024-05-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法
US20250000913A1 (en) * 2021-09-10 2025-01-02 Regents Of The University Of Minnesota Salmonella engineered for nontoxic colonization of tumors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5783196A (en) 1996-04-09 1998-07-21 University Of Maryland At Baltimore Gua mutants of shigella spp. and vaccines containing the same

Also Published As

Publication number Publication date
AU754795B2 (en) 2002-11-28
NO20005672L (no) 2001-01-15
PL344593A1 (en) 2001-11-05
NO20005672D0 (no) 2000-11-10
CA2328056C (en) 2010-07-06
WO1999058146A1 (en) 1999-11-18
ES2268864T3 (es) 2007-03-16
JP4363782B2 (ja) 2009-11-11
PL192378B1 (pl) 2006-10-31
HUP0101747A3 (en) 2002-03-28
EP1076566A1 (en) 2001-02-21
DE69932425D1 (de) 2006-08-31
DE69932425T2 (de) 2007-03-08
ZA200006381B (en) 2002-02-07
NZ508110A (en) 2002-10-25
MXPA00011075A (es) 2002-04-24
US6190669B1 (en) 2001-02-20
EP1076566B1 (en) 2006-07-19
JP2002514398A (ja) 2002-05-21
EP1076566A4 (en) 2005-01-05
CA2328056A1 (en) 1999-11-18
ATE333285T1 (de) 2006-08-15
HUP0101747A2 (hu) 2001-09-28
AU3740599A (en) 1999-11-29

Similar Documents

Publication Publication Date Title
DK1076566T3 (da) Svækkede mutanter af salmonella, som konstruktivt udtrykker Vi-antigenet
EP1032417A4 (en) BACTERIAL VACCINES CONTAINING ATTENUATED AUXOTROPHIC STRAINS OF LISTERIA EXPRESSING HETEROLOGIC ANTIGENS
DK142391D0 (da) Indretning til tilberedning, servering og opbevaring af f.eks. madvarer
EA200100773A1 (ru) Замещенные 1-гетероциклические диариламины
DK1113816T3 (da) Influenzavirus-vaccinesammensætning
RU92004496A (ru) Новые пиперазинил- и пиперидинилциклогексанолы
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
BR9916132A (pt) Composições e utilização das mesmas
FI913215A0 (fi) Additionspolymeriseringskatalysator, som aktiveras medelst oxidering.
DK1362597T3 (da) Antigene peptider, der er afledt af telomerase
GEP20105118B (en) Anti-vegf antibodies
TR199600128A2 (tr) Sekil verilebilir, isiya karsi stabilize edilebilir dokunmus bukleli mamuller.
DK1545597T3 (da) Immunstimulerende sammensætninger og fremgangsmåde til stimulering af en immunrespons
MX9102850A (es) Composiciones polimericas que contienen halogeno, estabilizadas.
NO910739L (no) Sementeringsmateriale for olje, gass- og vannbroenner.
DE69738512D1 (de) Epstein-barr virus type b ctl epitopen
DE69102205D1 (de) Oberflächenaktive Polyorganosiloxane.
ES1017793Y (es) Aparato refrigerador, especialmente frigorifico domestico.
FI912056A0 (fi) Kopplingsanordning, vilken omfattar efter varandra foeljande kopplingssektioner.
EA199800753A1 (ru) Бензотиофены, составы их содержащие и способы с их использованием
NO990849D0 (no) Substituerte 1,2,3,4-tetrahydro-2-dibenzofuranaminer og 2-aminocyklohepta (b) benzofuraner
IT8123022A0 (it) Frigorifero, congelatore o simile, elettrodomestico, in particolare perfezionato.
AU3487799A (en) Improved live attenuated viruses for use as vectors or vaccines
IT8223644A0 (it) Serracavo, particolarmente per elettrodomestici o simili.
IT9019153A1 (it) Valvola cardiaca artificiale, con elevatissimo grado di sicurezza